Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder.

Marinova Z, Chuang DM, Fineberg N.

Curr Neuropharmacol. 2017;15(7):977-995. doi: 10.2174/1570159X15666170320104237.

PMID:
28322166
2.

Management of obsessive-compulsive disorder comorbid with bipolar disorder.

Kazhungil F, Mohandas E.

Indian J Psychiatry. 2016 Jul-Sep;58(3):259-269. doi: 10.4103/0019-5545.192001. Review.

3.
4.

Open-Label trial on the effects of memantine in adults with obsessive-compulsive disorder after a single ketamine infusion.

Rodriguez CI, Levinson A, Zwerling J, Vermes D, Simpson HB.

J Clin Psychiatry. 2016 May;77(5):688-9. doi: 10.4088/JCP.15l10318. No abstract available.

5.

Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial.

Häge A, Banaschewski T, Buitelaar JK, Dijkhuizen RM, Franke B, Lythgoe DJ, Mechler K, Williams SC, Dittmann RW; TACTICS Consortium.

Trials. 2016 Mar 17;17(1):141. doi: 10.1186/s13063-016-1266-8.

6.

THE USE OF GLUTAMATE MODULATING DRUGS IN OBSESSIVE COMPULSIVE DISORDER.

MacMaster FP, Rosenberg DR.

Child Adolesc Psychopharmacol News. 2010 Dec;15(6):1-5. No abstract available.

7.

Glutamatergic agents for OCD and related disorders.

Pittenger C.

Curr Treat Options Psychiatry. 2015 Sep;2(3):271-283.

8.

Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial.

Pittenger C, Bloch MH, Wasylink S, Billingslea E, Simpson R, Jakubovski E, Kelmendi B, Sanacora G, Coric V.

J Clin Psychiatry. 2015 Aug;76(8):1075-84. doi: 10.4088/JCP.14m09123.

9.

Assessment and management of treatment-refractory obsessive-compulsive disorder in children.

Bloch MH, Storch EA.

J Am Acad Child Adolesc Psychiatry. 2015 Apr;54(4):251-62. doi: 10.1016/j.jaac.2015.01.011. Epub 2015 Jan 30. Review.

10.
11.

The use of medications approved for Alzheimer's disease in autism spectrum disorder: a systematic review.

Rossignol DA, Frye RE.

Front Pediatr. 2014 Aug 22;2:87. doi: 10.3389/fped.2014.00087. eCollection 2014. Review.

12.

Pharmacological treatment of obsessive-compulsive disorder.

Pittenger C, Bloch MH.

Psychiatr Clin North Am. 2014 Sep;37(3):375-91. doi: 10.1016/j.psc.2014.05.006. Epub 2014 Jul 24. Review.

13.

Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M; Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University, Antony MM, Bouchard S, Brunet A, Flament M, Grigoriadis S, Mendlowitz S, O'Connor K, Rabheru K, Richter PM, Robichaud M, Walker JR.

BMC Psychiatry. 2014;14 Suppl 1:S1. doi: 10.1186/1471-244X-14-S1-S1. Epub 2014 Jul 2. Review.

14.

The neurobiological link between OCD and ADHD.

Brem S, Grünblatt E, Drechsler R, Riederer P, Walitza S.

Atten Defic Hyperact Disord. 2014 Sep;6(3):175-202. doi: 10.1007/s12402-014-0146-x. Epub 2014 Jul 14. Review.

15.

An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder.

Bakhla AK, Verma V, Soren S, Sarkhel S, Chaudhury S.

Ind Psychiatry J. 2013 Jul;22(2):149-52. doi: 10.4103/0972-6748.132930.

16.

Glutamate and the Treatment of Obsessive-Compulsive Disorder.

Macmaster FP, Rosenberg DR.

Psychopharm Rev. 2010 May 1;45(5):33-40. No abstract available.

17.

Cycloserine induced mania.

Bakhla AK, Gore PS, Srivastava SL.

Ind Psychiatry J. 2013 Jan;22(1):69-70. doi: 10.4103/0972-6748.123636.

18.

Evidence-based pharmacotherapy for pediatric obsessive-compulsive disorder and chronic tic disorders.

De Nadai AS, Storch EA, McGuire JF, Lewin AB, Murphy TK.

J Cent Nerv Syst Dis. 2011 Jun 1;3:125-42. doi: 10.4137/JCNSD.S6616. Print 2011.

19.

Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.

Rodriguez CI, Kegeles LS, Levinson A, Feng T, Marcus SM, Vermes D, Flood P, Simpson HB.

Neuropsychopharmacology. 2013 Nov;38(12):2475-83. doi: 10.1038/npp.2013.150. Epub 2013 Jun 19.

20.

Isoforms of the neuronal glutamate transporter gene, SLC1A1/EAAC1, negatively modulate glutamate uptake: relevance to obsessive-compulsive disorder.

Porton B, Greenberg BD, Askland K, Serra LM, Gesmonde J, Rudnick G, Rasmussen SA, Kao HT.

Transl Psychiatry. 2013 May 21;3:e259. doi: 10.1038/tp.2013.35.

Supplemental Content

Support Center